LIMITATIONS AND DEFICIENCIES OF PHARMACO-ECONOMIC STUDIES IN THE RUSSIAN FEDERATION COMMENTS TO THE ARTICLE OF S. L. PLAVINSKIY ET AL. «PHARMACOECONOMIC ANALYSIS OF THE IMPACT ON THE BUDGET COSTS OF ADDING DEXMEDETOMIDINE (DEXDOR) INTO THE LIST OF VITAL AND ESSENTIAL DRUGS»

1. Protsenko D.N., Yaroshetskiy А.I., Suvorov S.G., Lekmanov А.U., Gel'fand B.R. on behalf of RuVent* research group Russian National Epidemiological Study of artificial pulmonary ventilation in the intensive care departments RuVent. Anesteziol. i Reanimatol., 2012, no. 2, pp. 64-72. (In Russ.)

2. Brennan A., Akehurst R. Modelling in health economic evaluation. What is its place? What is its value? Pharmacoeconomics, 2000, vol. 17, no. 5, pp. 445-459.

3. De Graeve D., Nonneman W. Pharmacoeconomic studies: pitfalls and problems. Int. J. Tech. Assess. Health Care, 1996, vol. 12, pp. 22-30.

4. Available at: http://www.mgfoms.ru/system/files/tarifnoe_soglashenie_territorialnoy_oms_2015_god.pdf

5. Available at: http://www.tfoms33.ru/orgoms/gts/11-normativedocs/383